Fig. 7. Effect of 2155-14 and its biotinylated analog on cell viability, levels of LC3 and cleaved lamin A/C in WM266-4 cells. (A) Results of cell viability study after 72 h treatment. (B) Quantification of western blot of cleaved lamin A/C in presence of 100 µM 2155-14/2529-1, 2529-3, 2529-5, and 2529-7. (C) Quantification of western blot of LC3-II in presence of 100 µM 2155-14/2529-1, 2529-3, 2529-5, and 2529-7. (D) Representative western blot of lamin A/C in presence of 100 µM 2155-14/2529-1, 2529-3, 2529-5, and 2529-7. (E) Representative western blot of LC3 in presence of 100 µM 2155-14/2529-1, 2529-3, 2529-5, and 2529-7. One-way analysis of variance (ANOVA) was used followed by Dunnett post hoc test. The data shown are the mean ± SD, n=3. ***** - p<0.0001, *** - p<0.001, ** - p<0.01, * - p<0.05, ns - not significant. Rap/CHQ = Rapamycin (5 µM)/Chloroquine (10 µM). Staurosporine was used at 1 µM. Note that 2529-3 and 2529-5 did not significantly increase levels of cleaved lamin A/C and LC3-II explaining their lower potency against WM266-4 cells. 2529-7 increased LC3-II to the levels of 2155-14/2529-1, while failing to increase levels of cleaved lamin A/C.